Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.60 |
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.54 |
| ▸ | MMP1 | P03956 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | FCER2 | P06734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533645 | 0.84 | PPARG (0.58) | PSMB5MMP2MMP9MME | |
| SCHEMBL1533647 | 0.84 | PPARG (0.58) | PSMB5MMP2MMP9MME | |
| SCHEMBL6250861 | 0.84 | PPARG (0.58) | PSMB5MMP2MMP9MME | |
| SCHEMBL8166212 | 0.82 | ANPEP (0.50) | PSMB5ANPEPMMP8 | |
| SCHEMBL4739403 | 0.81 | CYP2D6 (0.55) | — | |
| SCHEMBL8167073 | 0.81 | CYP2D6 (0.55) | — | |
| SCHEMBL9971659 | 0.81 | HDAC8 (0.47) | PSMB5ANPEPHDAC3HDAC4HDAC1 | |
| SCHEMBL2549448 | 0.81 | PSMB5 (0.55) | PSMB5HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL2722699 | 0.81 | ELANE (0.53) | PSMB5MMP1MMEFCER2 | |
| SCHEMBL1053745 | 0.81 | ELANE (0.53) | PSMB5MMP1MMEFCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | PSMB5 2646/4885ANPEP 356/4885HDAC3 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.